
![]() |
|---|
This webpage presents my CV in
a graphical link-rich form, for your browsing pleasure...it's
a bit slow loading, but if you can wait..
Välg stiget osäkert lovande smärtsam och du har valt rätt.
I was born and
raised in south
Minneapolis, a conurbation of 2 million
citizens straddling the Mississippi River halfway between the equator and
the north pole.
I grew up close to the shore of one of 29 lakes within the
City of
Minneapolis, created by the retreat of the last glaciers in the late
Pleistocene. The
lake is named Lake Harriet, in honor of the wife of Colonel Leavenworth,
who himself is honored (?) in the name of a renowned federal
prison
in Kansas. The Colonel and wife
actually lived in the area in the early part of the nineteenth century,
when
the Colonel was stationed at a frontier outpost called Fort
Snelling,
built on
a bluff at the confluence of the Minnesota and Mississippi Rivers. I
taught
geology there to gradeschool kids while I was a high school student
in the Minneapolis
Public Schools, hotbed of progressive and liberal thinking.Users of Mac/OS may download the haunting sound from off a Minnesota lake here.
THE PURPOSE OF EDUCATION IS NOT TO FILL AN EMPTY MIND, BUT TO OPEN A CLOSED ONE
There's a feeling I get when I look to the west
And my spirit is crying for leaving
--"Stairway to Heaven" by Robert Plant
From there I went west
to Berkeley, where I attended graduate school
at the University of
California, writing a Ph.D. dissertation in the lab of Fred H.
Wilt on
The Control of Histone Gene Expression
During Early
Sea Urchin Development, realizing the early influences I
picked up at
the U of M. My thesis committee was an odd assemblage of scientists whose
only
connection was an interest in developmental biology, including Daniel
Mazia (who first
isolated the mitotic apparatus in the 1950s from cleavage-stage sea urchin
embryos) and
John
Gerhart (who as a graduate student with Art Pardee in
the early
1960s demonstrated
regulatory and catalytic subunits of aspartyl transcarbamylase (ATCase),
fulfilling
predictions of allosteric control put forward by Jacob and Monod). Both
are now
members of the NAS. The youngest member of my committee was G. Steven
Martin, a new
faculty member at Berkeley studying the role of the transforming protein
Src in the
developmental switch between proliferation and differentiation. Using
mutants of Rous
Sarcoma Virus (RSV) temperature-sensitive for transformation, Steve and
his postdoc Kathy
Radke demonstrated phosphorylation at the permissive temperature (35oC) of
a 60 kD
protein which turned out to be pp60 Src, a protein which provided a
biochemical explanation
of neoplastic transformation. Another postdoc in Steve's lab, Tony
Pawson, moved the
focus of Src to phosphotyrosine, a modified amino acid first described in
1979 by Tony
Hunter at the Salk Institute. Hunter described a region in the pp60
Src
protein known as
the Src-homology domain 2, now simply known as
SH2,
which folds into a pocket in Src (and
other proteins from Hydra to Homo) capable of binding
phosphotyrosine.
SH2 domain
Swedish flag
Mora, Sweden
This was a town where the median
age was 14, and a young group
of energetic Swedes were set to make a name for themselves (probably so
they could get better jobs
farther south!). There I linked up with a young guest professor Rolf
Ohlsson and his wife Susan
Pfeifer, to look at oncogenes and growth factors in the control of cell
division in
early human development and placentation. I became a part of a team that
included a human
geneticist (Gö sta Holmgren) and a gynecologist (Jan Rydnert). We
managed
to publish two papers
in Cell and one in PNAS before we all left for more southerly climes
(Stockholm and Minnesota).
Swedish cabins in falu rö d
From there I moved back to the Land of the Free and the Home of
the Brave, settling in with Hal
Moses (photo at left)
at the Mayo Clinic to
study a protein called
transforming growth factor
type beta (TGFß). My project was to clone the cDNA for TGFß based on
rudimentary amino acid
sequence Hal had obtained from his extremely pure human TGFß.
We were beaten by a Genentech
group headed by Rik Derynck, so I turned my attention to another growth
factor related only by
name--transforming growth factor alpha (TGFa). There at Mayo, I got
together with a gastroenterologist
working in the Moses lab,
Robert J. Coffey, Jr., to look at the role of
TGFa in colonic neoplasia.
As a control for a Northern blot, prepared RNA from a culture of human
epidermal keratinocytes grown
by a dermatologist, Mark Pittelkow. Bob and I expected this RNA to
provide a negative control
for TGFa expression, and were certain that we had mislabeled the blot when
we first saw the whopping
signal in the keratinocyte lane. After finding that this transforming
growth factor was
expressed in cultured human keratinocytes, I went to the nursery at Mayo
to collect seven
penis foreskins to see whether TGFa expression was an artifact of culture
or a representation of
something real. It turned out that normal human (fore) skin expressed the
TGFa gene to a low
degree and also made the protein product, which resulted in a Nature paper
in 1987 co-authored with Derynck and one of his Genentech group.
After Moses left Mayo
to convert a rather moribund
Department of Anatomy at Vanderbilt University School of Medicine into a
dynamic Department
of Cell Biology and
Anatomy, I headed
east to Boston, to join the Center for Blood Research in close association
with
Harry Antoniades.
Harry was a biochemist
who first described insulin-like growth factor I (IGF-I) as "bound
insulin" in 1956, and had
abandoned his attempts to purify IGF-I from serum when he found an even
more potent mitogen called
platelet-derived growth factor (PDGF). Harry and Heldin truly "pushed the
envelope" on PDGF
in the late 1970s-early 1980s, purifying PDGF to homogeneity. Harry
provided the first peptide
sequence from PDGF in May 1983, showing in fact two N-termini defining two
related by distinct chains,
which he called A and B.
What I learned best under Harry's
mentorship
was how to write an NIH grant. I attempted my first NIH grant submission
in October 1986, as an Instructor in the Department of Pediatrics at
Harvard Medical School. The
proposal focused on understanding the structure of
PDGF. In that first NIH proposal, I spent half a
page describing a new technique called polymerase chain reaction (PCR),
which was executed at that time MANUALLY moving tubes through a series of
waterbaths, adding extra Klenow at each cycle. The proposal used PCR to
generate chimeric cDNA constructs using the PDGF B chain cDNA and the
newly-closed PDGF A chain cDNA as template. One of the most interesting
people I met at CBR was Edmond J. Yunis who was interested
in the relationship between aging and the immune system."SI QVAERIS PENINSULAM AMOENAM CIRCUMSPICE (If you seek a pleasant peninsula, look about you)
In January 1989, I was recruited
to the Center for Molecular Biology at
Wayne State University in Detroit, a
sprawling urban university in the midst of a moribund metropolis. Thanks
to visionary leadership from its President (David Adamany)
and the
retirement of Coleman ("Krugerrand") Young as Mayor of Detroit, both the
city and the
University (with its urban
mission are beginning a remarkable metamorphosis. The Center for
Molecular Biology began its life in 1987 as a Center for Research
Excellence, an offshoot of the
Michigan Strategic Fund (MSF). MSF was the
brainchild of Jamie
Kenworthy, a bright and creative politician in the
Michigan Department of Commerce. Like his mentor, then-Governor James
Blanchard, Kenworthy saw light at the end of the tunnel for the race
riot-scarred city in a Rust Belt state. Their answer was economic
diversification, to get the state off its addiction to the automotive
economy. Molecular Biology in Motown was one way to pump some new blood
into the ailing region.
The University's Center for Molecular Biology and its Department of
Molecular Biology were formally merged into one unit in October 1994, to
create an organized research unit, the Center for Molecular
Medicine and
Genetics. The question, What is molecular medicine...
Protein
tyrosine kinases.
